Thermo Fisher Scientific Inc. (TMO) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
Thermo Fisher Scientific Inc. (TMO) Morgan Stanley 24th Annual Global Healthcare Conference September 15, 2026 9:15 AM EDT
Company Participants
Marc Casper – Chairman & CEO
Conference Call Participants
Kallum Titchmarsh – Morgan Stanley, Research Division
Presentation
Kallum Titchmarsh
Morgan Stanley, Research Division
Amazing. Thank you, everyone, for joining us Day 2 of Morgan Stanley’s Global Healthcare Conference. I’m Kallum Titchmarsh. I run the Life Science Tools and Diagnostics team. Really pleased today to be joined by Marc Casper, Thermo’s CEO. We have a lot to discuss, I think, Marc, today.
Question-and-Answer Session
Kallum Titchmarsh
Morgan Stanley, Research Division
But maybe we can just kick off with a state of the union. We’ve seen, obviously, growing momentum throughout 2026 following perhaps a more dynamic few years. Q2 performance obviously came in ahead of guidance and obviously, the strongest growth we saw organically since 2021. So before we dive into each of the end markets and the segments specifically, how do you see the business today? And how has that environment evolved from your vantage point?
Marc Casper
Chairman & CEO
So Kallum, thanks for having us, and I’m joined today with two colleagues from Thermo Fisher, Raf Tejada, who is responsible for Investor Relations; and Sandy Pound, our Chief Communications Officer.
When I think about 2026, it’s setting up to be really an outstanding year. And it is a combination of improving end markets in the direction that we’ve expected to see that progression and very strong operational performance by the company. So as we exited the second quarter, it was good to be back to 5% organic growth, and we grew our EPS by 13% in the quarter. We’re able to raise our outlook for the full year and now expect organic growth to be about 4% this year. And actually progressing nicely in that range that we
